Skip to main content

Floxuridine Dosage

Medically reviewed by Last updated on Sep 9, 2020.

Applies to the following strengths: 0.5 g

Usual Adult Dose for Liver Metastasis in Adenocarcinoma

Recommended dose: 0.1 to 0.6 mg/kg/day by continuous arterial infusion; the higher dosage ranges (0.4 mg to 0.6 mg) are usually used for hepatic artery infusion because the liver metabolizes the drug (thus reducing the potential for systemic toxicity)

-Therapy can be given until adverse reactions appear. When these side effects have subsided, therapy may be resumed.
-The patient should be maintained on therapy as long as response to floxuridine continues.

Use: For the palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

No dose adjustments recommended.


-This drug should be given only by or under the supervision of a qualified physician who is experienced in cancer chemotherapy and intra-arterial drug therapy and is well versed in the use of potent antimetabolites.
-All patients should be hospitalized for initiation of the first course of therapy because of the possibility of severe toxic reactions.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

-This drug should be used with extreme caution in poor risk patients with impaired renal or hepatic function or a history of high-dose pelvic irradiation or previous use of alkylating agents.
-All patients should be hospitalized for the first course of therapy because of the possibility of severe toxic reactions.
-This drug is not intended as an adjuvant to surgery.
-This drug is a highly toxic drug with a narrow margin of safety. Patients should be carefully supervised since therapeutic response is unlikely to occur without some evidence of toxicity.

Patient advice:
-Patients should be informed of expected toxic effects, particularly oral manifestations.
-Patients should be alerted to the possibility of alopecia as a result of therapy and should be informed that it is usually a transient effect.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.